The antibody-drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical models., PMID:40297621
The antibody-drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical models., PMID:40297621
A ROR1 targeted bispecific T cell engager shows high potency in the pre-clinical model of triple negative breast cancer., PMID:40165319
A ROR1 targeted bispecific T cell engager shows high potency in the pre-clinical model of triple negative breast cancer., PMID:40165319
Integration of CD200, CD43 and ROR1 in Multiparameter Flow Cytometry (MFC) Routine Panels for the Differential Diagnosis of B-cell lymphoproliferative Disorders (B-LPDs)., PMID:39830795
Integration of CD200, CD43 and ROR1 in Multiparameter Flow Cytometry (MFC) Routine Panels for the Differential Diagnosis of B-cell lymphoproliferative Disorders (B-LPDs)., PMID:39830795
A novel ROR1-targeting antibody-PROTAC conjugate promotes BRD4 degradation for solid tumor treatment., PMID:39816690
A novel ROR1-targeting antibody-PROTAC conjugate promotes BRD4 degradation for solid tumor treatment., PMID:39816690
10 years of BiTE immunotherapy: an overview with a focus on pancreatic cancer., PMID:39759138
10 years of BiTE immunotherapy: an overview with a focus on pancreatic cancer., PMID:39759138
Identification of a novel anti-ROR1 nanobody through phage display and its biochemical characterization., PMID:39645564
Identification of a novel anti-ROR1 nanobody through phage display and its biochemical characterization., PMID:39645564
Therapeutic advances in the targeting of ROR1 in hematological cancers., PMID:39551787
Therapeutic advances in the targeting of ROR1 in hematological cancers., PMID:39551787
Highly specific detection of ROR1 cancer biomarker with bipolar electrochemiluminescence., PMID:39514011
Highly specific detection of ROR1 cancer biomarker with bipolar electrochemiluminescence., PMID:39514011
Tumour assessment of ROR1 levels in various adult leukaemia and lymphoma types., PMID:39495778
Tumour assessment of ROR1 levels in various adult leukaemia and lymphoma types., PMID:39495778
A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population., PMID:39438409
A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population., PMID:39438409
Engineering potent chimeric antigen receptor T cells by programming signaling during T-cell activation., PMID:39266656
Engineering potent chimeric antigen receptor T cells by programming signaling during T-cell activation., PMID:39266656
Unlocking the potential: advancements and future horizons in ROR1-targeted cancer therapies., PMID:39145866
Unlocking the potential: advancements and future horizons in ROR1-targeted cancer therapies., PMID:39145866
Novel humanized monoclonal antibodies against ROR1 for cancer therapy., PMID:39138527
Novel humanized monoclonal antibodies against ROR1 for cancer therapy., PMID:39138527
[Screening and validation of therapeutic targets for chronic sinusitis with nasal polyps based on proteomics]., PMID:39107122
[Screening and validation of therapeutic targets for chronic sinusitis with nasal polyps based on proteomics]., PMID:39107122
Variant Transcript of ROR1 ENST00000545203 Does Not Encode ROR1 Protein., PMID:39062146
Variant Transcript of ROR1 ENST00000545203 Does Not Encode ROR1 Protein., PMID:39062146
Receptor tyrosine kinase-like orphan receptor serves as a potential target in cancer immunotherapy., PMID:38973261
Receptor tyrosine kinase-like orphan receptor serves as a potential target in cancer immunotherapy., PMID:38973261
How receptor tyrosine kinase-like orphan receptor 1 meets its partners in chronic lymphocytic leukemia., PMID:38949887
How receptor tyrosine kinase-like orphan receptor 1 meets its partners in chronic lymphocytic leukemia., PMID:38949887
Development of Peptide Paratope Mimics Derived from the Anti-ROR1 Antibody and Long-Acting Peptide-Drug Conjugates for Targeted Cancer Therapy., PMID:38943600
Development of Peptide Paratope Mimics Derived from the Anti-ROR1 Antibody and Long-Acting Peptide-Drug Conjugates for Targeted Cancer Therapy., PMID:38943600
WNT5B drives osteosarcoma stemness, chemoresistance and metastasis., PMID:38689429
WNT5B drives osteosarcoma stemness, chemoresistance and metastasis., PMID:38689429
Using protein geometry to optimize cytotoxicity and the cytokine window of a ROR1 specific T cell engager., PMID:38455046
Using protein geometry to optimize cytotoxicity and the cytokine window of a ROR1 specific T cell engager., PMID:38455046
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer., PMID:38408999
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer., PMID:38408999
Associations between plasma metabolism-associated proteins and future development of giant cell arteritis: results from a prospective study., PMID:38310345
Associations between plasma metabolism-associated proteins and future development of giant cell arteritis: results from a prospective study., PMID:38310345
Enhancement of targeted therapy in combination with metformin on human breast cancer cell lines., PMID:38167105
Enhancement of targeted therapy in combination with metformin on human breast cancer cell lines., PMID:38167105
Clinico-Pathological and Prognostic Significance of a Combination of Tumor Biomarkers in Iranian Patients With Breast Cancer., PMID:37863762
Clinico-Pathological and Prognostic Significance of a Combination of Tumor Biomarkers in Iranian Patients With Breast Cancer., PMID:37863762
Current Treatments in Mantle Cell Lymphoma., PMID:37616519
Current Treatments in Mantle Cell Lymphoma., PMID:37616519
Antitumor activity of a ROR1 × CD3 bispecific antibody in non-small cell lung cancer., PMID:37499397
Antitumor activity of a ROR1 × CD3 bispecific antibody in non-small cell lung cancer., PMID:37499397
Future potential targets of antibody-drug conjugates in breast cancer., PMID:36996620
Future potential targets of antibody-drug conjugates in breast cancer., PMID:36996620
Investigating the inhibitory and penetrating properties of three novel anticancer and antimicrobial scorpion peptides via molecular docking and molecular dynamic simulation., PMID:36927377
Investigating the inhibitory and penetrating properties of three novel anticancer and antimicrobial scorpion peptides via molecular docking and molecular dynamic simulation., PMID:36927377
CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19., PMID:36537906
CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19., PMID:36537906
Preclinical Assessment of Immunogenicity and Protectivity of Novel ROR1 Fusion Proteins in a Mouse Tumor Model., PMID:36497309
Preclinical Assessment of Immunogenicity and Protectivity of Novel ROR1 Fusion Proteins in a Mouse Tumor Model., PMID:36497309
Periodontal ligaments enhance neurite outgrowth in trigeminal ganglion neurons through Wnt5a production induced by mechanical stimulation., PMID:36374171
Periodontal ligaments enhance neurite outgrowth in trigeminal ganglion neurons through Wnt5a production induced by mechanical stimulation., PMID:36374171
Richter Syndrome: From Molecular Pathogenesis to Druggable Targets., PMID:36230566
Richter Syndrome: From Molecular Pathogenesis to Druggable Targets., PMID:36230566
Development of Human Recombinant Antibodies Against ROR1 Tumor Antigen., PMID:36164620
Development of Human Recombinant Antibodies Against ROR1 Tumor Antigen., PMID:36164620
Frequently used antiemetic agent dexamethasone enhances the metastatic behaviour of select breast cancer cells., PMID:36107918
Frequently used antiemetic agent dexamethasone enhances the metastatic behaviour of select breast cancer cells., PMID:36107918
Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses., PMID:35881486
Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses., PMID:35881486
Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC., PMID:35659040
Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC., PMID:35659040
New Directions for Mantle Cell Lymphoma in 2022., PMID:35561299
New Directions for Mantle Cell Lymphoma in 2022., PMID:35561299
Retraction: Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells., PMID:35511798
Retraction: Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells., PMID:35511798
Crystal structure of the kringle domain of human receptor tyrosine kinase-like orphan receptor 1 (hROR1)., PMID:35506763
Crystal structure of the kringle domain of human receptor tyrosine kinase-like orphan receptor 1 (hROR1)., PMID:35506763
The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells., PMID:35456672
The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells., PMID:35456672
The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia., PMID:35358998
The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia., PMID:35358998
Memory B-cell like chronic lymphocytic leukaemia is associated with specific methylation profile of WNT5A promoter and undetectable expression of WNT5A gene., PMID:35333703
Memory B-cell like chronic lymphocytic leukaemia is associated with specific methylation profile of WNT5A promoter and undetectable expression of WNT5A gene., PMID:35333703
CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress., PMID:35311430
CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress., PMID:35311430
Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments., PMID:35266562
Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments., PMID:35266562
Aberrantly expressed Wnt5a in nurse-like cells drives resistance to Venetoclax in chronic lymphocytic leukemia., PMID:35210425
Aberrantly expressed Wnt5a in nurse-like cells drives resistance to Venetoclax in chronic lymphocytic leukemia., PMID:35210425
ROR1 for Lymphoid Cancers., PMID:38319244
ROR1 for Lymphoid Cancers., PMID:38319244
Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers., PMID:38319241
Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers., PMID:38319241
Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers., PMID:34805745
Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers., PMID:34805745
ROR1 and ROR2 expression in pancreatic cancer., PMID:34763666
ROR1 and ROR2 expression in pancreatic cancer., PMID:34763666
Therapeutic options for relapsed/refractory mantle cell lymphoma., PMID:34679161
Therapeutic options for relapsed/refractory mantle cell lymphoma., PMID:34679161
For research use only. Not for human or drug use.
